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Alzheimer’s disease (AD) is a major public health issue that impacts an estimated 
5%-10% of people in the 65-74-year range and nearly 50% of people over the age of 85 
(Bachman, Wolf, & Linn, 1992).  It is expected that the number of people afflicted with 
AD will increase exponentially as the “baby boomers” continue to age (Evans, 1990).  
Yet, despite the widespread prevalence and seriousness of this disorder, there remains 
much to learn about the effects certain genes play in the pathogenesis of AD.  As a result, 
there has been a proliferation of genetics studies and several genes have been identified 
as contributing to the pathogenesis of familial early-onset AD (FAD) and late-onset AD 
(LOAD).  As will be elaborated further at the end of this section, the purpose of the 
proposed study is to examine the impact of these genes on cognitive functioning, via 
meta-analyses of the accumulating literature.   
FAD is a rare form of AD characterized by an early onset, before the age of 65, 
and accounts for approximately 1%-2% of the entire population of individuals suffering 
from AD (Tanzi et al., 1987).  Many investigators believe the rates of FAD are closer to 
5%, arguing that it is frequently misdiagnosed or all together underaddressed by 
researchers (McMurtray, Clark, Christine, & Mendez, 2006; Sampson, Warren, & 
Rossor, 2004).  Missense mutations of the amyloid precursor protein (APP), presenilin-1 
(PSEN1), and presenilin-2 (PSEN2) genes all cause autosomal dominate FAD on 
chromosomes 21, 14, and 1, respectively (Rocchi, Pellegrini, Siciliano, & Murri, 2003).  
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The presence of any of these mutations usually results in onset of AD before the 
age of 65, although mutations on chromosome 1 appear to result in wider variability with 
onset ranging from 40 years of age to 80 (Bird et al., 1996).  In addition to earlier age of 
onset, mutations of these genes are also associated with an accelerated disease 
progression compared to late-onset AD (Ringman, Diaz-Olavarrieta, & Rodriguez, 2005).   
The prevalence rates of each of these mutations are, thus far, unclear.  For 
example, two studies examining mutations on chromosome 1 have resulted in widely 
discrepant estimates of 18% and 71% of all early-onset autosomal dominant AD (Chen et 
al., 2001; Cruts et al., 1998).  However, most studies seem to agree with the idea that 
mutations on chromosome 14 account for the majority of familial early-onset AD (see 
Cummings et al., 1998, for review).  The pathogenesis of these genetic mutations has also 
fueled the “amyloid hypothesis” as all three of these genetic mutations manipulate the 
same mechanism of action that results in the overproduction of Amyloid β (Ringman, 
2005).  Amyloid deposits produce widespread atrophy of several major structures found 
in the brain including the cerebral cortex and the hippocampus, which has been strongly 
linked to memory in previous studies (Squire, 1992).   
In addition to these genetic mutations, the presence of certain alleles of 
Apolipoprotein E (ApoE) on chromosome 19 have been implicated as significantly 
increasing the risk for developing LOAD after the age of 65.  ApoE is a plasma protein 
combined with a lipid that is responsible for carrying cholesterol and other fats through 
the bloodstream in order for these molecules to be broken down (Rocchi et al., 2003).  
ApoE is found in amyloid plaques and neurofibrillary tangles, both hallmark AD 
characteristics, and it is believed that it has some regulatory properties over their 
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deposition and formation (Harris et al., 2003).  Plaque formation may even require the 
presence of ApoE before amyloid plaques become toxic in the brain (Lahiri, Sambamurti, 
& Bennett, 2004).  The ApoE gene has three common allelic variations: epsilon 2 (ε2), 
epsilon 3 (ε3), and epsilon 4 (ε4).  Every individual inherits one allele of ApoE from each 
of their parents.  Therefore, there are six possible genotypes that can be inherited: ε2ε2, 
ε2ε3, ε2ε4, ε3ε3, ε3ε4, and ε4ε4 (Lahiri et al., 2004).  Each of these allelic variations has 
been studied in their relation to onset of AD.  The ε3 variant occurs most frequently 
throughout the general Caucasian population with an occurrence rate of 79% and it 
neither significantly increases nor decreases the risk of developing LOAD (Corder et al., 
1996; Lahiri et al., 2004).  The ε2 and ε4 variations occur significantly less with 
occurrence rates at approximately 8% and 14%, respectively (Seshadri, Drachman, & 
Lippa, 1995; Small, Rosnick, Fratiglioni, & Backman, 2004; Tischa et al., 2004).  It is 
important to note that the ApoE allelic distribution among cognitively healthy individuals 
has been shown to be different across various ethnic backgrounds resulting in imprecise 
prevalence estimates for the entire population (Tischa et al., 2004).  The ApoE ε2 allele is 
positively associated with survival and longevity among older adults and is therefore 
considered a protective factor against AD (Corder et al., 1996).  Conversely, the 
increased risk for AD in the presence of the ε4 allele is the single most replicated finding 
in AD genetics research (Cacabelos, 2003).  Approximately 40%-60% of all Alzheimer’s 
disease carriers possess the ε4 allele of ApoE, which is two to three times higher than is 
typically found in the general population (Parker et al., 2005).  A meta-analysis of all the 
different variants of ApoE indicated that heterozygous ApoE ε4 (ε2ε4 or ε3ε4) carriers 
are 3 to 4 times more likely to develop LOAD whereas Homozygous ApoE ε4 (ε4ε4) 
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allele carriers are 10 to 12 times more likely to develop LOAD (Farrer et al., 1997).  
Although it has a significant effect, the presence of ApoE ε4 remains merely a risk factor 
for developing AD as studies have shown that it has no effect on families that are 
genetically predisposed to develop FAD (Van Broeckhoven et al., 1994). 
Many recent studies have started to focus on the effects of APP, PSEN1, PSEN2, 
and ApoE ε4 on various cognitive domains for nondemented carriers.  It has been found 
that mutation carrying individuals scored higher on tests of object naming and object 
perception when compared to the LOAD group; however, individuals with LOAD scored 
significantly higher on measures of verbal ability (Warrington, Agnew, Kennedy, & 
Rossor, 2001).  In addition, studies have found that mutation carrying individuals scored 
significantly lower on measures related to executive functioning, working memory, and 
visuospatial tasks when compared to noncarrying controls; however, there was no 
significant difference in the scores between the carriers and noncarriers on verbal 
memory and language scores (Ringman et al., 2005).  In addition, the presence of ApoE 
ε4 is associated with poorer performance on tests of global cognitive functioning, 
episodic memory, and executive functioning (Small et al., 2004).  No differences have 
been found for ApoE ε4 carriers on cognitive measures of primary memory, attention, 
visuospatial skill, verbal ability, and perceptual speed (Small et al., 2004).  Furthermore, 
the zygosity of the ApoE ε4 carriers has a significant impact on the magnitude of 
cognitive deficits measured.  Homozygotic ApoE ε4 carriers exhibit significantly poorer 
performance on global cognitive functioning and episodic memory when compared to 
noncarriers; however, heterozygotic carriers are not significantly different than 
noncarriers (Small et al., 2004).  As expected, individuals carrying the ApoE ε2 allele 
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demonstrate better performance, as compared to ε3 homozygotes, whereas ApoE ε4 
carriers perform significantly worse on cognitive measures (Small et al., 2004).  This 
indicates that the ε2 allele has a beneficial impact on cognitive performance even in 
nondemented populations. 
Although the existing literature includes meta-analytic studies of prominent 
genetic markers for AD, there are no meta-analytic studies examining the role of APP, 
PSEN1, and PSEN2 on cognitive factors.  Therefore, it is the focus of this present study 
to try and sort through the extensive literature concerning AD to determine the effect size 
of each of the genes, both familial and late-onset AD, on various domains of cognitive 
functioning by conducting multiple meta-analyses.  As is consistent with previous 
literature, it is hypothesized that ApoE ε4 will have the largest effect contributing to 
cognitive deficits while carriers of ApoE ε2 will score the highest on cognitive measures.  
In addition, the effect sizes of APP, PSEN1, and PSEN2 will be measured across various 
cognitive domains to determine which, if any, have the most significant impact on AD 
carrier’s cognitive functioning.  This will allow for better accuracy when diagnosing AD 










REVIEW OF LITERATURE 
Alzheimer’s disease (AD) is a major public health issue that impacts an estimated 
5%-10% of people in the 65-74 year range and nearly 50% of people over the age of 85 
(Bachman, Wolf, & Linn, 1992).  It is estimated that over 20 million people have been 
diagnosed with AD worldwide (Itzhaki, Wozniak, Appelt, & Balin, 2004).  In the United 
States alone there are over 4.5 million people diagnosed with AD and this number is 
expected to increase exponentially as the “baby boomers” begin to extend life expectancy 
(Evans, 1990).   
As the most common form of dementia, AD accounts for approximately two 
thirds of all cases, and is characterized by irreversible, neurodegenerative damage of the 
brain (Hendrie, 1998).  Despite the widespread prevalence and seriousness of this 
disorder there is currently no known cure for AD, although some pharmacological 
treatments, such as acetylcholinesterase inhibitors, have been found to be useful at 
slowing disease progression (Fu, Zhang, & Sun, 2005).  The lack of an effective cure is 
largely because there are multiple risk factors, many of which remain unidentified, that 
increase the likelihood that someone will suffer from AD. 
Normal aging typically results in a decrease in cortical and hippocampal volume, 
often causing mild declines in memory abilities, but AD is far more severe (Morrison & 
Hof, 1997).  Characterized by insidious onset, AD is progressive and ultimately reveals 
multiple cognitive deficits which, in addition to impaired memory and thinking, may 
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include sleep disturbances, disorientation, change(s) in personality and behavior, inability 
to follow directions, and problems with language and communication.  The current 
Diagnostic and Statistical Manual of Mental Disorders (text revision [DSM–IV–TR]; 
American Psychiatric Association, 2000) further requires that these cognitive deficits be 
accompanied by aphasia (disability in articulating ideas or comprehending spoken or 
written language), apraxia (disability in performing coordinated movements or 
manipulating objects), or agnosia (disability in interpreting sensory stimuli). 
Risk Factors 
There are several known risk factors that have been shown to increase the 
likelihood of developing AD.  Several studies have indicated that women are at a 
significantly higher risk for developing dementia than men, especially at very old ages 
(Bachman et al., 1992; Fratiglioni et al., 1997).  In part, this finding reflects the fact that 
women, on average, live longer than men.  However, even in studies that have controlled 
for age, women appear to be at a slightly greater risk for AD than men (Schoenberg, 
Anderson, & Haerer, 1985).  One possible explanation that has been offered for this 
discrepancy is that women may have greater susceptibility to a specific genotype that 
increases the likelihood of developing AD (Payami et al., 1996). 
Other studies have shown that cardiovascular disorders, like hypertension, 
significantly increase the risk of developing AD (Skoog & Gustafson, 2003).  More 
specifically, high systolic blood pressure has been associated with an increased risk for 
hippocampal atrophy which greatly increases the chances of developing AD (Launer et 
al., 2000).  The hippocampus is a part of the brain critically involved in the formation and 
storage of memories (Squire, 1992).  Other known vascular factors and conditions that 
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increase the risk for developing AD include: diabetes, hypercholesterolemia, 
hyperhomocystinemia, and transient ischemic attacks (Iadecola & Gorelick, 2003; 
Michikawa, 2003). 
Contaminants in the environment have also been linked to increasing the risk of 
developing AD.  For example, aluminum and aluminum containing products, such as 
deodorant, have been strongly linked with AD (Graves et al., 1990).  Furthermore, studies 
have shown that prolonged exposure to different types of aluminum can result in large 
cellular depletions during hippocampal formation (Miu, Andreescu, Vasiu, & Olteanu, 
2003).  In addition, aluminum is found in abundance within the neuritic plaques and 
neurofibrillary tangles that are typically associated with AD (Harrington & Wischik, 
1995). 
A history of head trauma has also been shown to increase the likelihood of 
developing AD (Mayeux et al., 1993), but only in combination with specific genotypes 
(Mayeux et al., 1995).  In addition to head trauma, some studies have indicated that the 
circumference of the head and size of the brain are correlated with development of AD.  
Individuals with smaller heads have a greater risk for AD even after adjusting for 
confounding variables such as weight, height, and gender; however the genotype still 
plays an important synergistic role (Graves, Mortimer, & Bowen, 2001).  Likewise, 
individuals with larger brains may be able to mask the effects of AD for a longer period 
of time before being officially diagnosed (Mortimer, Borenstein, & Gosche, 2005). 
There has also been a substantial body of research looking at the effects of 
genetics as a risk factor for developing AD.  One indication that genetics likely play an 
integral role in AD was the observation that people with Down’s syndrome almost 
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invariably get AD if they survive into middle age (Lott & Head, 2005).  Because Down 
syndrome is caused by trisomy on chromosome 21, researchers began to investigate the 
relationship between chromosomes and AD (Lott & Head, 2005).  With the proliferation 
of genetics studies, it is now widely held that there are at least two distinct sub-types of 
Alzheimer’s disease: familial early-onset AD (FAD) and late-onset AD (LOAD).  Each 
of these sub-types, and the genetic underpinnings, will be reviewed.  However, it is 
important to first understand the relevant mechanisms of action before investigating 
which genes on specific chromosomes are contributing to the different types of AD. 
Mechanisms of Action 
Alzheimer’s disease is known to result when brain proteins fail to fold regularly 
and clump together, thereby interfering with normal neuronal activity.  Two kinds of 
abnormal proteins have been identified as related to Alzheimer’s disease: amyloid and 
tau.  Amyloid produces neuritic plaques, structures formed from degenerating axons and 
dendrites, in various synapses found throughout the brain (Kalat, 2003).  Tau produces 
neurofibrillary tangles, structures formed from degenerating structures found within 
neuronal cell bodies.  The amount of amyloid and tau buildup present in an individual’s 
brain can be directly influenced by their genetic makeup (Kalat, 2003). 
Most cases of AD are complex in that they appear to be inherited in a non-
Mendelian fashion; several genes may interact to cause the disease (Parker et al., 2005).  
Although several of these genes have been identified, scientists believe that there are 
multiple genetic combinations that have yet to be explored.  Thus far, research indicates 
that there are four chromosomes typically involved in the pathogenesis of AD.  Three of 
these chromosomes (21, 14, and 1) are found as missense mutations (the meaning of a 
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readable genetic message has changed due to a substitution on one base of DNA) that 
cause autosomal dominate FAD (Rocchi, Pellegrini, Siciliano, & Murri, 2003).  
Autosomal dominance refers to one parent carrying a genetic mutation on one of the 
identified chromosomes resulting in a 50% chance that the child will also develop FAD 
(Rocchi et al., 2003).  Therefore, if both parents suffer from FAD the child will almost 
always (greater than 99%) develop the disorder as well.  Although these genetic 
mutations have very high specificity, the vast majority of AD carriers only develop the 
disorder later in life (Rocchi et al., 2003).  Furthermore, some carriers are known to be 
sporadic and occur in families without a specific autosomal dominant pattern of 
inheritance (Cummings, Vinters, Cole, & Khachaturian, 1998). 
The fourth chromosome (19) that has been heavily implicated in AD progression 
significantly increases the risk that an individual will develop the disease.  Carriers of 
certain allelic combinations on this chromosome most typically develop AD after the age 
of 65 (Kalat, 2003). 
Although genes play a vital role in many of the cases of AD, it is important to 
note that environmental factors also significantly contribute to onset and progression of 
the disease.  In the largest population-based twin study of AD to date (2006), researchers 
found that the concordance rates of AD varied with age of onset for the disorder 
suggesting there are non-genetic lifestyle factors that can affect both risk and timing of 
AD (Gatz et al., 1997).  In addition, cross-cultural studies have shown that the Yoruba 
people of Nigeria have a much lower incidence of AD than do Americans, including 
African Americans (Hendrie, 2001).  The Yoruba do not develop AD even if they have 
the same allelic combinations of certain chromosomes that increase the risk in 
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Americans.  It is currently believed that this decreased vulnerability is the result of the 
Yorubas’ low-calorie, low-fat, low-sodium diet. 
Familial Early-Onset AD (FAD) 
FAD is a rare form of AD characterized by an early onset, before the age of 65 
(Kalat, 2003).  This is typically problematic for both the individuals suffering from FAD 
and their families as they are still actively involved in providing and caring for the 
member of their family with AD.  The prevalence rates of FAD have been estimated to 
affect only 1%-2% of the entire population of people suffering from AD (Tanzi et al., 
1987).  However, many investigators argue that the rates of FAD should be significantly 
higher than what is reported due to the difficulty in differentially diagnosing FAD.  
Recent studies illustrate this point by showing that FAD is frequently misdiagnosed as a 
different form of dementia or is all together under addressed by researchers in their 
investigations of AD (McMurtray, Clark, Christine, & Mendez, 2006; Sampson, Warren, 
& Rossor, 2004). 
Amyloid precursor protein, Presenilin-1, and Presenilin-2 
 FAD is, to date, known to result from genetic mutations on three chromosomes: 
21, 14, and 1.  Other genes have been implicated as contributing to FAD, but these are 
the most widely researched genes at this time.  These mutations impact the encoding for 
the amyloid precursor protein (APP) on chromosome 21, the presenilin-1 (PSEN1) 
protein on chromosome 14, and the presenilin-2 (PSEN2) protein on chromosome 1 
(Rocchi et al., 2003).  The presence of any of these mutations usually results in onset of 
AD before the age of 65, although mutations on chromosome 1 appear to result in wider 
variability with onset ranging from 40 years of age to 80 (Bird et al., 1996).  The 
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variability of impact associated with a mutation on chromosome 1 has been interpreted as 
suggestive of incomplete penetration.  In addition to earlier age of onset, mutations of 
these genes are also associated with an accelerated disease progression compared to late-
onset AD (Ringman, Diaz-Olavarrieta, & Rodriguez, 2005).   
There are other anomalous symptoms that are not present in LOAD, but are 
frequently found in FAD including: spastic paraparesis or quadriparesis (weakness of the 
lower or combined lower and upper extremities), early myoclonus (a condition of 
abnormal contraction of muscles or portions of muscles), seizures, or a presentation with 
predominantly frontal lobe dysfunction (Ringman, 2005).  These discrepant effects could 
reflect the aggressive nature of FAD or, perhaps, the impact of the younger age of the 
brain at the onset of the disorder (Ringman, 2005).   
The prevalence rates of each of these mutations are, thus far, unclear.  For 
example, two studies examining mutations on chromosome 1 have resulted in widely 
discrepant estimates of 18% and 71% of all early-onset autosomal dominant AD (Chen et 
al., 2001; Cruts et al., 1998).  However, most studies seem to agree with the idea that 
mutations on chromosome 14 account for the majority of familial early-onset AD (see 
Cummings et al., 1998, for a review).  The pathogenesis of these genetic mutations has 
also fueled the “amyloid hypothesis” as all three of these genetic mutations manipulate 
the same mechanism of action that results in the overproduction of Amyloid β (Ringman, 
2005).   
Brain cells contain a large protein called amyloid precursor (APP) that is cleaved 
to form a smaller protein, 40 amino acids long, referred to as Aβ40 (Kalat, 2003).  Some 
individuals have a genetic mutation in which APP is cleaved into a slightly longer chain 
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of amino acids known as Aβ42 (Kalat, 2003).  The extra proteins are believed to clump 
together over time and damage the membranes of axons and dendrites (Lorenzo et al., 
2000).  The majority of people afflicted with AD accumulate amyloid plaques containing 
Aβ42 before the onset of behavioral symptoms (Selkoe, 2000).  Amyloid deposits produce 
widespread atrophy of several major structures found in the brain including the cerebral 
cortex and the hippocampus, which has been strongly linked to memory in previous 
studies (Squire, 1992).   
Several mutations of the APP gene on chromosome 21 have been described in 
patients with FAD.  These mutations occur at the cleavage sites in the precursor protein at 
the beginning and end of the peptide (Cummings et al., 1998).  The mutated APP gene 
affects the production of Aβ in numerous ways, but appears to significantly increase the 
levels of the highly toxic Aβ42. (Hardy, 1997).  The actual function of APP in healthy 
brains is still poorly understood.  However, it has been suggested that APP may function 
as an autocrine factor by stimulating cell proliferation and cell adhesion as well as 
supporting nerve growth factor on neurite outgrowth (Rocchi et al., 2003).  Both of the 
presenilin mutations on chromosomes 14 and 1 are very similar in their structure and they 
both increase the production of Aβ, particularly Aβ42.  PSEN1 and PSEN2 mutations 
regulate the levels of Aβ40 and Aβ42 because they both have γ-secretase activity, the 
enzyme involved in transmembrane metabolism of APP (Haass & De Strooper, 1999; Li 
et al., 2000).   
Until recently, very few studies measured the differences in cognitive functioning 
between individuals with FAD and LOAD as they were thought to be clinically similar.  
However, more recent studies have started to focus on the cognitive differences between 
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FAD and LOAD as well as the differences of each individual mutation linked to FAD.  It 
has been found that mutation carrying individuals scored higher on tests of object naming 
and object perception when compared to the LOAD group; however, individuals with 
LOAD scored significantly higher on measures of verbal ability (Warrington, Agnew, 
Kennedy, & Rossor, 2001).  PSEN1, on chromosome 14, has been studied within at-risk 
populations in order to determine the effect of the mutation on various cognitive factors.  
One study found the carriers of the PSEN1 mutation scored significantly lower on 
measures related to executive functioning, working memory, and visuospatial tasks when 
compared to noncarrying controls; however, there was no significant difference in the 
scores between the PSEN1 carriers and noncarriers on verbal memory and language 
scores (Ringman et al. , 2005). 
Late-Onset AD (LOAD) 
 The majority of AD cases have a late onset, usually developing after the age of 65 
(Kalat, 2003).  The symptomology present in someone with LOAD is nearly identical to 
individuals with FAD with the few noted exceptions above.  Much like FAD, the genetics 
of LOAD are complex with the possible involvement of several genes and a synergistic 
interaction with environmental factors (Kamboh, Minster, Feingold, & DeKosky, 2006).  
However, no known inherited autosomal dominant genetic mutations exist in LOAD.  
This indicates that many of the gene markers associated with LOAD do not definitively 
predict the onset of AD.  However, there have been several genes identified that 
significantly increase the susceptibility and risk associated with the onset of sporadic 
LOAD.  Some of these genes appear to have a larger effect on LOAD, particularly genes 
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on chromosome 19, however there remain several other genes on multiple chromosomes 
currently being investigated as potentially contributing to LOAD (Kamboh, 2004). 
Chromosome 6 
A human leukocyte antigen (HLA) allele on chromosome 6 has been linked with 
an earlier age of onset for AD (Payami et al., 1997).  An allele is any of the alternative 
forms of a gene that may occur at a given locus.  The HLA is the major 
histocompatibility complex in humans, responsible for allowing the cells of one tissue to 
survive in the presence of cells of another tissue (Payami et al., 1997).  Certain alleles on 
HLA genes may be interfering with the immune system’s ability to effectively combat 
LOAD (Payami et al., 1997).   
Chromosome 7 
 There has been some evidence linking nitric oxide synthase (NOS3), an enzyme 
located on chromosome 7 responsible for the synthesis of nitric oxide, with LOAD 
pathology (Marsden et al., 1993).  Some studies have shown a high concentration of the 
NOS3 endothelial product (eNOS) found in hippocampal pyramidal neurons, a brain 
region that has commonly been linked to the onset of LOAD (Doyle & Slater, 1997).  
Also, individuals suffering from LOAD have an increased expression of eNOS in the 
brain (De la Monte & Bloch, 1997).  It is thought that the stress caused by this increased 
synthesis of nitric oxide in the brain leads to neuronal death (De la Torre & Stefano, 
2000).  Further research has shown that a specific genotype of NOS3 is overrepresented 





 Lipoproteins are complex particles composed of fatty lipids, making them highly 
soluble and permeable in the bloodstream, and proteins (Kalat, 2003).  Lipoproteins 
deliver fats in the form of cholesterol throughout the body and are primarily characterized 
by their density: high density lipoprotein (HDL), low density lipoprotein (LDL), and very 
low density lipoprotein (VLDL; Rocchi et al., 2003).  Several specific genotypes of these 
lipoproteins have been implicated on various chromosomes as possible susceptibility 
agents for LOAD.  The very low density lipoprotein receptor (VLDL-R) gene, located on 
chromosome 9, is suspected to be involved in LOAD development.  VLDL-R works as a 
receptor for apolipoproteins (Rocchi et al., 2003), a heavily implicated contributor to 
LOAD which will be discussed in greater depth later in this review when overviewing 
chromosome 19.  Further evidence that VLDL-R significantly affects LOAD is supported 
by studies that have found VLDL-R in abundance on specific microglia that are strongly 
associated with senile plaques (Christie, Chung, Rebeck, Strickland, & Hyman, 1996).  
Although VLDL-R has received some support, there remains some controversy 
concerning its lack of effect for distinct populations.  More specifically, it appears that 
certain allelic combinations of VLDL-R with apolipoprotein significantly increase the 
likelihood of developing LOAD in Japanese populations and European Caucasians as 
opposed to Caucasian populations from other countries (Okuizumi et al., 1995; 
Yamanaka et al., 1998). 
Chromosome 10 
 The insulin degrading enzyme gene (IDE), located on chromosome 10, is partly 
responsible for the degradation and removal of Aβ that has been secreted by microglial 
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cells and neurons (Vekrellis et al., 2000).  Therefore, it is suggested that malfunctioning 
IDE may be contributing to LOAD by leaving too much secreted Aβ in the brain.  Other 
studies have found a susceptibility locus on chromosome 10 which increases the 
expression of Aβ deposition resulting in an increased risk for developing LOAD (Myers 
et al., 2000). 
Chromosome 12 
 Several recent studies have implicated Chromosome 12 as being a site of action 
where multiple abnormalities can increase the risk of developing LOAD.  One 
abnormality involves α2-Macroglobulin, a proteinase inhibitor.  Protease is a type of 
enzyme that is responsible for breaking down proteins in the central nervous system (Qiu, 
Strickland, Hyman, & Rebeck, 1999).  Therefore, α2-Macroglobulin serves to stop the 
breaking down of certain proteins found in the brain, including Aβ (Qiu et al., 1999).  α2-
Macroglobulin was identified as being a disease locus during a genetic linkage study with 
a sample of patients and controls from Northern Spain.  The results of this study 
implicated that α2-Macroglobulin only had a significant effect on the development of 
LOAD if the patients were over the age of 81 (Alvarez et al., 1999).  However, other 
studies have found that α2-Macroglobulin is not dependent on the patient’s age to still 
have a significant effect on the development of LOAD (Dodel et al., 2000).  Other studies 
have rejected the effects of α2-Macroglobulin as a risk-factor for LOAD all together 
(Gibson et al., 2000).  Therefore, further research needs to be conducted to determine 
whether or not α2-Macroglobulin has a significant effect on LOAD. 
The low-density lipoprotein receptor-related protein gene (LRP), the main ApoE 
receptor in neurons, is coded for by alleles on chromosome 12 (Rebeck, Reiter, 
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Strickland, & Hyman, 1993).  LRP enables secreted amyloid precursor proteins to gain 
entry into a cell without passing through the cell membrane through the process of 
endocytosis (Kounnas et al., 1995).  Due to its close proximity to α2-Macroglobulin on 
chromosome 12, LRP has received recent attention as a potential explanation for the 
disparate research linking α2-Macroglobulin with the development of LOAD.  One of the 
LRP alleles is associated with an earlier age of onset as well as one of the 
neuropathological hallmarks of AD, a significantly greater abundance of neuritic or senile 
plaques (Cummings et al., 1998).  However, as is consistent with the research focusing on 
the role α2-Macroglobulin plays in the development of LOAD, several studies have 
found contradicting results when examining LRP.  Some studies have found that it takes 
different variations in the involvement of one or both polymorphisms in order to 
significantly contribute to LOAD development (Verpillat et al., 2001).  Other studies 
have had difficulty replicating the finding that LRP has any effect on LOAD at all 
(Hatanaka et al., 2000). 
A small number of recent studies have focused on the transcriptional factor gene 
on chromosome 12, LBP-1c/CP2/LSF, and its effects on the development of LOAD.   
LBP-1c/CP2/LSF was examined because it is proximally similar to LRP on chromosome 
12 and LBP-1c/CP2/LSF controls the expression of α2-Macroglobulin (Rocchi et al., 
2003).  Two studies have independently confirmed that a specific allele of LBP-
1c/CP2/LSF exerts a protective effect against the development of sporadic or LOAD.  It 
is suggested that the absence of this protective allele may actually increase the risk of 
developing LOAD, although this has yet to be addressed in a research study (Lambert et 
al., 2001; Taylor et al., 2001). 
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Chromosome 19 
 Chromosome 19 includes the gene that has the strongest support for increasing the 
susceptibility to develop LOAD.  There is near universal acceptance among AD 
researchers that certain allelic combinations of apolipoprotein E significantly increase the 
risk of LOAD as well as modifying the risk for other factors including the genes that 
contribute to FAD.  Apolipoprotein E (ApoE) is a plasma protein combined with a lipid 
that is responsible for carrying cholesterol and other fats through the bloodstream in order 
for these molecules to be broken down (Rocchi et al., 2003).  It has also been associated 
with neuronal repair as it is aids in the relocation of cholesterol during neuronal growth 
and after injury (Mahley, 1988; Menzel, Kladetzky, & Assmann, 1983).  ApoE is 
synthesized primarily by the liver, neurons and astrocytes in the brain, as well as 
macrophages (a type of white blood cell that destroys bacteria) and monocytes (Siest et 
al., 1995).  ApoE is found in amyloid plaques and neurofibrillary tangles and it is 
believed that it has some regulatory properties over their deposition and formation (Harris 
et al., 2003).  Plaque formation may even require the presence of ApoE before amyloid 
plaques become toxic in the brain (Lahiri, Sambamurti, & Bennett, 2004).   
The ApoE gene has three common allelic variations: epsilon 2 (ε2), epsilon 3 (ε3), 
and epsilon 4 (ε4).  Every individual inherits one allele of ApoE from each of their 
parents.  Therefore, there are six possible genotypes that can be inherited: ε2ε2, ε2ε3, 
ε2ε4, ε3ε3, ε3ε4, and ε4ε4 (Lahiri et al., 2004).  Each of these allelic variations has been 
studied in their relation to onset of AD.  The ε3 variant occurs most frequently 
throughout the general Caucasian population with an occurrence rate of 79% (Lahiri et 
al., 2004).  The ε2 and ε4 variations occur significantly less with occurrence rates at 
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approximately 8% and 14%, respectively (Seshadri, Drachman, & Lippa, 1995; Small, 
Rosnick, Fratiglioni, & Backman, 2004; Tischa et al., 2004).  It is important to note that 
the ApoE allelic distribution among cognitively healthy individuals has been shown to be 
different across various ethnic backgrounds resulting in imprecise prevalence estimates 
for the entire population (Tischa et al., 2004).   
The ApoE ε3 allele is the most common form found in the general population and 
it is believed to play a neutral role in the development of LOAD (Corder et al., 1996).  In 
other words, it neither significantly increases nor decreases the risk associated with the 
development of LOAD.  The ApoE ε2 allele is positively associated with survival and 
longevity among older adults (Corder et al., 1996).  Therefore, ApoE ε2 is a protective 
factor against developing LOAD; however, it is the rarest allele of ApoE on chromosome 
19 (Corder et al., 1996). 
The ApoE ε4 allele is a powerful risk factor for the development of LOAD.  The 
increased risk for AD in the presence of the ε4 allele is the single most replicated finding 
in AD genetics research (Cacabelos, 2003).  It is believed that ApoE ε4 affects the 
development of LOAD because it increases the production of Aβ and significantly 
increases the number of neuritic plaques found in the brain; however, it appears that 
ApoE ε4 does not affect the level of neurofibrillary tangles that are commonly associated 
with patients suffering from AD (Gomez-Isla et al., 1996).  In addition, ApoE ε4 carriers 
have smaller hippocampal volumes than that of noncarriers which could impact their 
episodic memory performance (Cohen, Small, Lalonde, Friz, & Sunderland, 2001).   
Recently, researchers have begun studying the interaction between ApoE ε4 and 
the herpes simplex 1 virus (HSV-1), responsible for common cold sores, and its effects 
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on LOAD (Itzhaki et al., 2004).  HSV-1 typically remains latent in individuals who carry 
it and only visibly expresses itself occasionally.  It appears that carriers of ApoE ε4 are 
more susceptible to HSV-1’s expression whereas carriers of ApoE ε2 experience the 
effects of HSV-1 less than is typical of the population (Itzhaki et al., 2004).  As a result, 
the virulent pathogen HSV-1 is more active and damaging in the brain of ApoE ε4 
carriers and may be contributing to LOAD.  One case study indicated that viral 
inflammation, such as that caused by HSV-1, can result in the neurofibrillary tangles and 
degeneration in the brain commonly associated with both FAD and LOAD (Ball, 2003).  
In addition, some studies have shown that carriers of both ApoE ε4 allele and HSV-1 are 
more likely to develop LOAD than populations with either HSV-1 with a different allele 
of ApoE or ApoE ε4 with no HSV-1 (Itzhaki et al., 2004).  ApoE ε4 carriers also have 
more HSV-1 DNA in the brain regions that are most commonly associated with AD, 
lending further support to the interaction of ApoE ε4 and HSV-1 as a risk factor (Itzhaki 
et al., 2004).  Further research still needs to be conducted to determine if HSV-1 is a 
correlate or a causal mechanism in the development and onset of AD. 
Approximately 40%-60% of all Alzheimer’s disease carriers possess the ε4 allele 
of ApoE, which is two to three times higher than is typically found in the general 
population (Parker et al., 2005).  One study assessed the risk associated with developing 
LOAD in the presence of ApoE ε4.  The overall lifetime risk of developing LOAD 
increases from 14% to 29% in the presence of at least one ApoE ε4 and reduced to 9% if 
no ε4 is present (Seshadri et al., 1995).  A meta-analysis of all the different variants of 
ApoE indicated that heterozygous ApoE ε4 (ε2ε4 or ε3ε4) carriers are 3 to 4 times more 
likely to develop LOAD whereas Homozygous ApoE ε4 (ε4ε4) allele carriers are 10 to 
 22 
12 times more likely to develop LOAD (Farrer et al., 1997).  In addition, the ε4 allelic 
variation was shown to be a significant risk factor across diverse ethnic populations in 
both men and women, although women appear to be at a slightly higher risk (Farrer et al., 
1997).  Although having only one copy of the ApoE ε4 allele significantly increases the 
likelihood that an individual will develop LOAD, many people carry two copies of the ε4 
allele and show no signs of LOAD.  Therefore, it is believed that the presence of ApoE ε4 
is a risk factor, but is neither necessary nor sufficient to cause the disease (Farrer et al., 
1997).  Further support for ApoE ε4 as simply a risk factor was provided by a study that 
found that ApoE ε4 had no significant effect on families that are genetically predisposed 
to develop FAD (Van Broeckhoven et al., 1994). 
Several studies have also looked at the effects of ApoE ε4 on nondemented 
populations to see if it impacts various domains of cognitive performance (Bretsky, 
Guralnik, Launer, Albert, & Seeman, 2003; Small et al., 2000).  More specifically, 
studies have found that ApoE ε4 carriers have difficulty on cognitive tasks pertaining to 
episodic memory functioning and executive functioning (Wilson, Bienias, Berry-Kravis, 
Evans, & Bennett, 2002).  In addition, no significant differences were found for ApoE ε4 
carriers on tasks related to primary memory or visuospatial functioning (Yip, Brayne, 
Easton, & Rubinsztein, 2002).  Regardless of these results, there remain large 
discrepancies in the literature concerning the effect of ApoE ε4 on cognitive 
performance.  Some studies have reported that ApoE ε4 has a significant effect on 
cognitive performance among cognitively impaired individuals, but not cognitively 
healthy individuals (Small, Basun, & Backman, 1998).  Other studies have observed 
significant effects of ApoE ε4-related difficulties among cognitively healthy older adults 
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(Wilson et al., 2002).  One reason for this discrepancy is that some studies have failed to 
control for age (Small et al., 2004).  This is a necessary control because ApoE ε4, as a 
risk factor for developing LOAD, loses its potency with age (Farrer et al., 1997).   
A different meta-analysis combined all of the relevant literature to reconcile the 
differences among these studies (Small et al., 2004).  This study looked at the effects of 
ApoE ε4 on certain cognitive domains while examining age as a possible modifying 
variable.  In addition, this study examined the widely reported protective effects of ApoE 
ε2 as a protective factor against developing LOAD.  More specifically, this study 
examined whether ApoE ε2 conveys a similar advantage to cognitive performance as it 
does to increased longevity (Small et al., 2004).   
The results of the meta-analysis indicated significant group differences between 
ApoE ε4 carriers and non-carriers across several domains of cognitive functioning.  More 
specifically, the presence of ApoE ε4 was associated with poorer performance on tests of 
global cognitive functioning, episodic memory, and executive functioning (Small et al., 
2004).  In contrast, no differences were found for ApoE ε4 carriers on cognitive measures 
of primary memory, attention, visuospatial skill, verbal ability, and perceptual speed.  
These findings are consistent with previous literature that ApoE ε4 only affects specific 
domains of cognitive functioning while others remain unaffected (Cohen et al., 2001; 
Wilson et al., 2002).  There remains some question as to whether ApoE ε4 affects a 
carrier’s visual attention or working memory when compared to non-ε4 carriers 
(Parasuraman, Greenwood, & Sunderland, 2002).  Like previous studies, this meta-
analysis found that age had an inverse relationship with the magnitude of ApoE ε4-
related deficits although the effect was very small.  Furthermore, the zygosity of the 
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ApoE ε4 carriers had a significant impact on the magnitude of cognitive deficits 
measured.  The homozygotic ApoE ε4 carriers exhibited significantly poorer performance 
on global cognitive functioning and episodic memory when compared to noncarriers; 
however, heterozygotic carriers were not significantly different than noncarriers (Small et 
al., 2004).  As expected, individuals carrying the ApoE ε2 allele demonstrated better 
performance, as compared to ε3 homozygotes, whereas ApoE ε4 carriers performed 
significantly worse (Small et al., 2004).  This indicates that the ε2 allele has a beneficial 
impact on cognitive performance even in nondemented populations. 
Hypotheses 
 Although the existing literature includes meta-analytic studies of prominent 
genetic markers for AD, particularly of ApoE allele combinations, there are no meta-
analytic studies examining the role of APP, PSEN1, and PSEN2 on cognitive factors.  
Therefore, it is the focus of the proposed study to try and sort through the extensive 
literature concerning AD to determine the effect size of each of these genes, within both 
familial and late-onset AD, on various domains of cognitive measures by conducting 
meta-analyses of the literature.   
As is consistent with previous literature, it is hypothesized that ApoE ε4 will have 
the largest effect contributing to cognitive deficits while carriers of ApoE ε2 will score 
the highest on cognitive measures.  In addition, the effect sizes of APP, PSEN1, and 
PSEN2 will be measured across various cognitive domains to determine which, if any, 
have the most significant impact on AD carrier’s functioning.  This will allow for better 






 An electronic database search using PsycINFO, MEDLINE, and PubMed was 
performed for published studies in English from January 1991 to August 2008.  Studies 
published after 1991 were selected as this was the first time that mutations of APP on 
chromosome 21 were identified as resulting in Alzheimer’s disease (Goate et al., 1991).  
In addition, this time period covers the universe of articles looking at genetic mutations 
and genetic risk factors for Alzheimer’s disease as ApoE ε4-related deficits, PSEN1, and 
PSEN2 were discovered shortly after APP (Corder et al., 1993; Levy-Lahad et al., 1995; 
Sherrington et al., 1995).  These computer searches included search terms such as: 
Alzheimer’s disease, Apolipoprotein E, APOE, amyloid precursor protein, APP, 
presenilin, PS1, PS-1, PS2, PS-2, PSEN, chromosome (21, 19, 14, 1), genetic, cognitive 
performance, memory, neuropsych, nondemented, preclinical, and cognition.   
In addition to using electronic databases, the reference lists of the studies 
identified during the computer search were thoroughly examined to identify additional 
studies.  Also, the abstracts and table of contents of several relevant journals, such as 
Psychology and Aging, Neurology, Neuropsychological Abstracts, Archives of 
Neurology, and Neurobiology of Aging were hand searched to locate any potentially 
missed studies.  Finally, informal consultation was sought from experts in geriatric 
populations in order to identify any additional studies or journals relevant to the research 
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questions.  All of these methods of literature retrieval were conducted to ensure an 
exhaustive review of the literature and subsequent results are representative of true effect 
sizes. 
Eligibility Criteria 
All studies selected for inclusion needed to have partitioned their participants into 
either the ApoE, APP, PSEN1, or PSEN2 genotypes in order to be included in the meta-
analysis.  In addition to identifying the participants’ genotype, the studies needed to 
include at least one standardized measure of cognitive performance to be analyzed.  The 
studies also must have included participants that were cognitively intact with no 
diagnosed cognitive impairments or traumatic brain injuries documented.  Finally, the 
studies needed to include sufficient statistical information to allow for effect sizes to be 
calculated.  This included: means and standard deviations; p values, various effect sizes, 
or F values; and sample sizes.  Authors of studies that otherwise met the inclusion 
criteria, but were missing relevant statistics, were contacted in order to retrieve the 
relevant information for the analyses. 
Outcome Measures 
The studies included in the meta-analysis assessed their participants’ cognitive 
functioning using different measures for similar cognitive functions.  Therefore, all of the 
cognitive tests were organized into several broad domains of cognitive functioning.  
These domains are based on the typical taxonomy found in the neuropsychological 
assessment literature (Lezak, Howieson, Loring, Hannay, Fischer, 2004).  The cognitive 
domains in which the individual measures were categorized include: attention, episodic 
memory, executive functioning, global cognitive ability, perceptual speed, primary 
 27 
memory, verbal ability, and visuospatial functioning.  Table 1 contains examples of many 



























Attention Paced Auditory Serial Addition Test; Stroop 




Auditory Verbal Learning Test; Benton Visual 
Retention Test; Buschke Selective Reminding 
Test; California Verbal Learning Test; Fuld Object 
Recognition Test; Randt Short Story Memory 
Test; Wechsler Memory Scale; various tests of 
immediate recall, delayed recall, and recognition. 
Executive 
Functioning 
Arithmetic; Mazes; Stroop Color/Word 
(Interference); Trailmaking-B; Two-Back Task; 




Heim AH4-Part 1; Mattis Dementia Rating Scale; 
Mini-Mental State Examination; Modified Mini-
Mental State Examination; Wechsler Adult 
Intelligence Scale- Full Scale IQ Score 
Perceptual 
Speed 
Digit Symbol Coding, Symbol Digit Modalities 
Test, various measures of reaction time 
Primary 
Memory 
Digit Span Forward and Backward 
Verbal Ability Boston Naming Test; Controlled Oral Word 
Association Test; Spot the Word Test; National 
Adult Reading Test; Wechsler Adult Intelligence 
Scale- Verbal IQ measures; various tests of 
category and letter fluency 
Visuospatial 
Skill 
Block Design; Clock Test; various measures of 
construction and figure copying 
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Statistical Analysis 
Studies that met the inclusion criteria were analyzed following the methods and 
procedures proposed for a random-effects design by Hedges and Olkin (1985).  When 
compared to other meta-analytic methods, this approach has been shown to be more 
reasonable and convergent with previous findings pertaining to various topics in the 
literature (Johnson, Mullen, & Salas, 1995).  The data from each study was used to 
calculate an effect size estimate, Hedge’s g, which is the difference between the AD 
groups (APP, PS1, PS2, or ApoE ε4-carriers) and the control group (non-carriers) divided 
by the pooled standard deviation.  Therefore, Hedge’s g represents the standardized mean 
difference between the AD and control groups in each study and was chosen because it 
corrects for biases due to small sample sizes (Hedges & Olkin, 1985).  The effect size, d, 
was used to pool the results across studies for each of the genetic mutations and risk 
factors.  It represents the standardized mean difference between studies within each 
mutation, weighted by the sample sizes of the individual studies (Hedges & Olkin, 1985).  
Weighting the studies affects the variance estimate for each study because variance 
estimates for studies with larger sample sizes are more precise than those for studies with 
smaller effect sizes (Lipsey & Wilson, 2001).  Negative effect sizes indicate poorer 
performance on the cognitive measures for the AD groups when compared to non-
carriers.  Also, several studies used multiple cognitive measures for one domain (e.g., 
PASAT and Trails A to measure attention).  As a result, an averaged effect size of the 
measures for each domain was obtained for each study following the procedures outlined 
by Cohen (1988).  The initial baseline data was used in the meta-analysis for studies that 
administered cognitive measures at multiple time points. 
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The chi-square statistic, Q, was also calculated to test for homogeneity of results 
across studies.  If significant, it indicates that there may be other characteristics affecting 
the magnitude of the effect sizes (Hedges & Olkin, 1985).  In addition to the Q-statistic, 
the I2 index was calculated as a measure of the degree of inconsistency in the study 
results.  It represents the percentage of variance across studies that is not attributed to 
chance alone (Higgins, Thompson, Deeks, & Altman, 2003).  For the moderator analysis, 
QW was calculated as a measure of the heterogeneity of studies within categories.  In 
addition, QB was calculated to represent the difference between categories of the 
moderator variable.  If significant, QB indicates that the moderating variables are 
significantly affecting the results.  All of the outlined statistical procedures are consistent 
with previous meta-analyses that examined the effects that ApoE and mutations for AD 
have on nondemented individuals’ cognitive performance (Bäckman, Jones, Berger, 
Laukka, & Small, 2005; Small et al., 2004).  All analyses were conducing using the 
statistical software Comprehensive Meta Analysis, Version 2.0 (Borenstein, Hedges, 
Higgins, & Rothstein, 2005). 
Moderator Variables 
 In addition to calculating overall effect sizes, potential moderating variables that 
are associated with the magnitude of effect sizes were included for examination.  While a 
test of heterogeneity increases confidence that the studies share a common effect size, it 
is still necessary to fully address the effect of potential variables’ impact on the effect 
sizes observed (Hall & Rosenthal, 1991).  Therefore, two moderating variables that 
typically influence ApoE-related cognitive deficits were examined; age and the zygosity 
of ApoE ε4 carriers.  Several studies have shown that increases in age significantly 
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decrease the magnitude of the effect attributed to ApoE ε4 (Farrer et al., 1997; Small et 
al., 2004).  Therefore, age was treated as a continuous variable to plot the magnitude of 
the observed effect sizes between ApoE ε4 carriers and ApoE ε4-noncarriers’cognitive 
performance.  In addition to age, ApoE ε4 zygosity (homozygous or heterozygous) and 
the potential compensatory effects of ε2 zygosity were examined for the analyses.   
For the meta-analysis, no moderating variables were examined as possibly 
affecting the effect size magnitude of APP, PSEN1, and PSEN2 genetic mutations.  This 
is largely because the inheritance of any one of these genetic mutations from only one 
parent results in a near 50% likelihood that the offspring will develop FAD as well 
(Rocchi et al., 2003).  Therefore, unlike ApoE ε4 carriers, it is thought that there are very 
few potential moderators on the effect size magnitude from genetic mutations, including 
the presence of ApoE ε4.  While the inheritance of a genetic mutation from both of the 
parents resulting in further cognitive deficiencies associated with only one mutation is 
possible, the actual sample size of participants identified in the relevant studies was too 
small to include as a moderating variable in the analyses.   
Publication Bias 
One common criticism of meta-analyses is that they have historically 
overestimated effect sizes as a result of the “file-drawer problem.”  The file-drawer 
problem is the result of publication bias in which the set of available studies in peer-
reviewed journals is not representative of all studies ever conducted on that topic 
(Rosenthal, 1979).  There are many studies that are unpublished because their results are 
not statistically significant and are sitting in researchers’ “file drawers.”  To examine the 
possibility of publication bias, the fail-safe N was calculated on the mean weighted effect 
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sizes contributed by each study (collapsing across the cognitive domains) to determine 
the number of nonsignificant studies that would need to be included to nullify the results.  
Rosenthal (1979) recommends testing this estimated fail-safe N value against 5k + 10 (k 
= number of studies), a conservative estimate of the existing unpublished null-finding 
studies.  Rosenthal (1979) indicates that the meta-analysis results are an accurate estimate 
of the true effect size if the fail-safe N is relatively large when compared to the estimated 





















 Table 2 displays the characteristics of the studies included in the ApoE meta-
analysis.  Originally, 176 studies were identified for inclusion in the analyses.  Many of 
these studies were conducted by the same researchers on the same cohort resulting in 
multiple publications.  To avoid dependency in the observations, the most comprehensive 
study from that research group was included.  Comprehensive studies included the largest 
sample sizes and widest breadth of cognitive measures and are thought to be the best 
representation of the original research sample.  As a result, 49 studies were eliminated 
after examining the characteristics of the study and the respective participant samples.  22 
additional studies were eliminated as the participants had documented cognitive deficits 
including, but not limited to: different types of dementia, Parkinson’s disease, and 
traumatic brain injury.  39 studies were missing relevant data to calculate the effect sizes 
and were contacted for the necessary information; 11 authors responded to the request 
with the data; 7 authors refused to send the data; the remaining 21 authors never 
responded to the request for the information.  In total, cognitive test results were obtained 
from 40,942 cognitively healthy individuals across 77 studies.   
 Only five studies focusing on APP, PSEN1, and PSEN2 were identified to be 
included in the analyses.  Of those five studies, three were by the same authors and the 
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remaining two collected data from the same extended family.  As a result of the 




Characteristics of Studies Included in the Meta-Analysis 
First author Year Cognitive Domains n,  ε4 
present 




Alexander 2007 EF, EM, PM, PS, VA 91 324 28 
Askar 2005 EF, EM, VA 17 61 62.3 
Bartzokis † 2006 EM, GC 12 53 66.1 
Bathum † 2006 GC 138 597 92 
Baum 2006 GC 40 189 78.3 
Berr 1996 EM 274 869 65 
Blair 2005 EM, PS, VA 2418 5477 56.8 
Bondi 1999 AT, EF, EM, GC, PM, PS, 
VA, VS 
43 90 69.5 
Bookheimer 2000 EM 16 14 62.5 
Bunce 2005 EM, PM, VS 49 118 82.8 
Burkhardt 2004 EM, GC 64 117 66.1 
Calhoun-
Haney 
2005 GC 22 28 71.9 
Caselli 2002 EF, EM, GC, PM, VA, VS 84 42 55.1 
Deary 2002 GC 121 345 79.1 
Deeny 2008 GC 25 52 59.8 
den Heijer 2002 GC 261 688 72.3 
Dik 2000 EM 213 653 73.2 
Driscoll 2005 AT, EF, EM, GC, VS 16 16 78.2 
Espeseth 2008 AT, EF, EM, GC, PS 37 59 64.5 
Ewers 2008 GC 6 31 66.7 
Flicker 2004 EM, GC, PS 74 225 78.9 
Flory 2000 EM, GC, PM 61 159 45.5 
Frisoni 2005 GC 4 21 69 
Gilbert 2004 EM, GC, VA 19 19 71.4 
Helkala 1995 AT, EF, EM, GC, VA, VS 278 634 73.9 
Hofer 2002 EM, PS, VA 95 339 75.9 
Houston 2005 AT, EF, EM, GC, VA, VS 24 28 76.2 
Hu 2006 GC 106 349 74.1 
Hwang 2006 GC 20 91 75 
Irie 2008 GC, PS 602 1945 74.7 
Jessen 2007 EM 213 839 80.1 
Johnson 2006 AT, EF, EM, VA 11 53 55 
Jorm 2007 EM, GC, PM, PS, VA 1757 4638 42.7 
Juva † 2000 GC 68 245 85 
Kim 2002 EM, GC, VA, VS 74 392 70.1 
Klages 2003 EM, GC 42 167 76.8 
Kryscio 2006 AT, EF, EM, VA 137 330 Not 
Reported 
Lehmann † 2006 EM 666 1451 72.5 
Levy 2004 EM, PS, VA, VS 61 115 59.4 
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Moffat 2000 GC 13 13 69.1 
Mondadori 2007 EM 13 21 22.3 
Moore 2005 GC 19 16 74.5 
Mosconi 2008 EM, GC, PS, VA 13 15 59 
Newman 2000 GC, VA 29 29 59.4 
Nilsson 2006 GC, EM 777 1918 58.8 
O’Brien 2004 AT, EF, EM, GC, PM, VA 13 25 72.9 
O’Hara 1998 EM, GC, PS, VA 22 61 74 
Payton † 2006 AT, EM, GC, PS, VA 185 555 62.9 
Peavy 2007 EM, GC 29 55 78.4 
Persson 2006 GC, VA 30 30 66.3 
Plassman 1997 EM, GC, PS, VA 6 14 62.5 
Pomara 2005 EM, GC, VA 24 40 66.1 
Reiman 1996 EM, EM, GC, PM, VA, 
VS 
11 22 56 
Reynolds 2006 EM, PM 160 386 65 
Riley 2000 EM, GC, VA, VS 34 207 81 
Robson 2002 AT, EM, GC, VA 34 52 59 
Rosen 2002 EF, GC, PM 21 21 62.2 
Sager 2005 EF, EM, GC, VA, VS 204 248 53 
Salo 2001 EM, GC, VA 12 34 89 
Savitz 2007 AT, EF, EM, PM, VA 60 165 47.9 
Schmidt 1996 EF, EM, PM, PS, VA 39 175 60.5 
Small, B. J. 2000 AT, EF, EM, GC, VA 91 322 72.9 
Small, B. J. 1998 EM, GC, PM, VA, VS 20 54 81.8 
Small, G. 2000 EM, GC 27 27 66.4 
Smith 1998 GC 90 251 79.7 
Steed 2001 AT, EF, EM, PS 30 81 64.5 
Sun 2007 AT, EM, GC, VA, VS 4 26 68.8 
Swan 2006 EF, EM, PS 70 256 78.9 
Tagarakis 2007 EM, GC, PM 33 104 69.5 
Tardiff 1997 EF, EM, PM, PS 17 48 61.3 
Tohgi 1997 GC 14 40 58.7 
Tupler 2007 EM, GC 73 90 65.8 
Wang 2006 EM, GC 4 16 75.1 
Wilson, 
Bienas 
2002 GC 158 511 75.5 
Wilson, 
Schneider 
2002 EM 186 542 75.9 
Wishart 2006 AT, EF, EM, VA 13 22 66.6 
Yaffe 1997 EF, GC, PS 271 1479 71.1 
  Total n 11108 29834  
 
Note. ε4 = epsilon 4 allele of the apolipoprotein E gene; Cognitive domains: AT = 
attention, EM = episodic memory, EX = executive functioning, GC = global cognitive 
ability, PM = primary memory, PS = perceptual speed, VA = verbal ability, VS = 
visuospatial functioning. 






 A total of 227 effect sizes were extracted across all eight cognitive domains.  
Table 3 displays the mean weighted effects sizes (d-values) for each of the eight 
cognitive domains calculated across all of the studies included in the analyses.  ApoE ε4 
carriers performed more poorly than ApoE non-ε4 carriers on all of the cognitive 
domains; significant differences were found on episodic memory (k  = 56, d = -.14, 95% 
confidence interval = -.21, -.07, p < .001), global cognitive functioning (k  = 55, d = -.05, 
95% confidence interval = -.10, -.004, p < .05), executive functioning (k = 22, d = -.06, 
95% confidence interval = -.12, -.004, p < .05), and perceptual speed (k = 18, d = -.07, 
95% confidence interval = -.13, -.01, p < .05).  Although the observed effect sizes are 
small according to Cohen’s conventions (1988), some of the observed effects are larger 







Effect Sizes for the Eight Domains of Cognitive 
Functioning 
  Sample Size      






r Q I 2 (%) 
Episodic 
Memory 














-.03 72.63* 25.65 
Verbal ability 33 5,953 14,638 - -.05, -.002 36.72 12.86 
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Note. k = number of studies; ApoE = apolipoprotein E; ε4+ = ε3/ε4, ε4/ε4; ε4- = ε2/ε2, 
ε2/ε3, ε3/ε3; d = mean weighted effect size, CI = confidence interval, r = effect size 
expressed as correlation coefficient, Q = within domain homogeneity, I2 = percentage 
of heterogeneity due to study differences. 




The results indicated significant heterogeneity of effect sizes for episodic memory 
(Q = 241.07, p < .001), global cognitive ability (Q = 72.63, p < .05), perceptual speed (Q 
= 34.11, p < .01), and primary memory (Q = 125.61, p < .001), indicating that moderator 
variables are influencing the results. 
 Meta-regression was used to measure the impact of increasing age on the 
observed effect sizes between ApoE-ε4 carriers and ApoE non-ε4 carriers on episodic 
memory, global cognitive ability, and perceptual speed (Figures 1, 2, and 3 in Appendix 
A, respectively).  Increasing age was a significant predictor of larger effect sizes for both 
episodic memory (Qm= 6.67, p < .01) and global cognitive ability (Qm = 5.16, p < .05); 
however, age was not a significant predictor of effect size changes for perceptual speed 
(Qm= .38, p = .54).  This indicates that the differences observed between ApoE-ε4 
carriers and ApoE non-ε4 carriers on episodic memory and global cognitive ability 








-.03 18.08 0 
Perceptual 
Speed 














Attention 15 974 2,454 -.03 -.11, 
.05 
-.02 7.26 0 
Visuospatial 
functioning 
13 902 1,992 -.02 -.11, 
.06 
-.01 8.57 0 
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 Table 4 displays the mean weighted effect sizes (d-values) when controlling for 
ApoE ε4 zygosity on measures of episodic memory and global cognitive ability.  The six 
remaining cognitive domains were not examined as a result of too few studies reporting 
the cognitive results according to ApoE ε4 zygosity.  ApoE ε4 homozygote carriers 
(ε4/ε4) performed significantly poorer than ApoE non-ε4 carriers on measures of episodic 
memory (k = 12, d = -.18, 95% confidence interval = -.34, -.02, p < .05); however, no 
significant differences were found between ApoE ε4 heterozygote carriers (ε3ε4) and 
ApoE non-ε4 carriers on measures of episodic memory (k = 12, d = -.04, 95% confidence 
interval = -.09, .01, p = .12).  In addition, no significant differences were found between 
ApoE ε4 homozygote carriers and ApoE ε4 heterozygote carriers on measures of episodic 
memory (Qb = 2.73, p = .10).  On measures of global cognitive ability, no significant 
differences were found between ApoE ε4 homozygote carriers and ApoE non-ε4 carriers 
(k = 7, d = -.14, 95% confidence interval = -.31, .03, p = .11).  Likewise, ApoE ε4 
heterozygote carriers did not perform significantly different than ApoE non-ε4 carriers on 
measures of global cognitive ability (k = 7, d = .02, 95% confidence interval = -09, .14, p 
= .72).  Finally, no significant differences were found between ApoE ε4 homozygote 
carriers and ApoE ε4 heterozygote carriers on measures of global cognitive ability (Qb = 
2.33, p = .13). 
 Table 5 displays the mean weighted effect sizes (d-values) when comparing the 
presence of ApoE ε2 against ApoE ε4 on measures of episodic memory and global 
cognitive ability.  The six remaining cognitive domains were not examined as a result of 
too few studies reporting the presence of ApoE ε2.  ApoE ε2 carriers (ε2/ε2, ε2,ε3) did 
not perform significantly different than the control group (ApoE ε3/ε3) on measures of 
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episodic memory (k = 6, d = .09, 95% confidence interval = -.05, .22, p = .20).  Likewise, 
no significant differences were found between ApoE ε4 carriers (ε3/ε4, ε4/ε4) and the 
control group (ApoE ε3/ε3) on measures of episodic memory (k = 6, d = -.08, 95% 
confidence interval = -.17, .02, p = .11).  However, ApoE ε2 carriers performed 
significantly better than ApoE ε4 carriers on measures of episodic memory (Qb = 3.88, p 
< .05).  On measures of global cognitive ability, ApoE ε2 carriers did not perform 
significantly different than the control group (k = 4, d = .05, 95% confidence interval = -
.17, .28, p = .65).  Likewise, ApoE ε4 carriers did not perform significantly different than 
the control group on measures of global cognitive ability (k = 4, d = .001, 95% 
confidence interval = -.11, .11, p = .99).  Finally, ApoE ε2 carriers did not perform 
significantly different than ApoE ε4 carriers on measures of global cognitive ability (Qb = 





Effect Sizes for Episodic Memory and  Global Cognitive Ability When Controlling 
for ApoE- ε4 Zygosity 
  Sample Size     




d 95% CI Qw Qb 
Episodic 
Memory 
       
HMZ ε4 12 592 16,046 -.18* -.34, -.02 26.1** 




       
HMZ ε4 7 137 5,148 -.14 -.31, .03 5.71 
HTZ ε4 7 1,496 5,148 .02 -.09, .14 17.03 
2.33 
 
Note. k = number of studies; ApoE = apolipoprotein E; ε4+ = ε3/ε4, ε4/ε4; ε4- = ε2/ε2, 
ε2/ε3, ε3/ε3; d = mean weighted effect size, CI = confidence interval, Qw = within 
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domain homogeneity, Qb = between groups homogeneity; HMZ ε4 = homozygote epsilon 
4 carriers (ε4/ε4); HTZ ε4 = heterozygote epsilon 4 carriers (ε3/ε4). 






Effect Sizes for Episodic Memory and  Global Cognitive Ability When Comparing 
ApoE-ε2 Against ApoE-ε4 
  Sample Size     
Domain k ε2+ or 
ε4+ 
ε3/ ε3 d 95% CI Qw Qb 
Episodic 
Memory 
       
ApoE ε2+ 6 270 1,460 .09 -.05, .22 1.94 




       
ApoE ε2+ 4 178 1,054 .05 -.17, .28 4.51 
ApoE ε4+ 4 456 1,054 .001 -.11, .11 1.33 
.16 
 
Note. k = number of studies; ApoE = apolipoprotein E; ε2+ = (ε2/e2, e2/e3); ε4+ = 
ε3/ε4, ε4/ε4; d = mean weighted effect size, CI = confidence interval, Qw = within 
domain homogeneity, Qb = between groups homogeneity. 
* p < .05.     ** p < .01. 
 
Publication Bias 
 Figure 4 in Appendix A displays a funnel plot to visually assess for any 
publication bias.  When publication bias is present, the funnel plot would have multiple 
studies with few participants and large effect sizes near the bottom of the plot.  This is 
largely because studies with a smaller number of participants are less likely to get 
published unless the effect sizes are large.  As can be seen in Figure 4, the effect sizes are 
symmetrically distributed with no publication bias visually present.  In addition, the fail-
safe N of 533 calculated across all 77 studies when collapsing cognitive domains 
exceeded the estimate of 395 unretrieved or existing unpublished studies with 
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nonsignificant findings.  This indicates that the observed significant effects cannot be 
















 The results of the meta-analysis indicated statistically significant group 
differences between ApoE ε4 carriers and ApoE non-ε4 carriers across multiple domains 
of cognitive functioning.  More specifically, ApoE ε4 carriers performed significantly 
poorer on measures of episodic memory, global cognitive ability, executive functioning, 
and perceptual speed.  Overall, the weighted mean differences between the groups ranged 
from middling to small, ranging from .003 to .14 standard deviations.  No significant 
differences were observed for the domains of attention, primary memory, verbal ability, 
and visuospatial skill. 
 The decreased performance observed on certain cognitive abilities as a result of 
the presence of ApoE ε4 is consistent with many other studies.  Specifically, several 
researchers have found that ApoE ε4 carriers perform worse on measures of episodic 
memory (Bondi, Salmon, Galasko, Thomas, & Thal, 1999; Flory, Manuck, Ferrell, Ryan, 
& Muldoon, 2000; Levy et al., 2004; Nilsson et al., 2006; Wilson, Bienias et al., 2002), 
global cognitive ability (Deary et al., 2002; Hwang et al., 2006), executive functioning 
(1995; Rosen, Bergeson, Putnam, Harwell, & Sunderland, 2002; Swan, Lessov-
Schlaggar, Carmelli, Schellenberg, & La Rue, 2006) and perceptual speed (Blair et al., 
2005).  Furthermore, nonsignificant findings is consistent with many other studies for 
attention (Small et al., 2004; Sun et al., 2007), primary memory (Rosen et al., 2002), 
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verbal ability (O’Hara Helkala et al., et al., 1998; Small et al., 2000), and visuospatial 
skills (Levy et al., 2004). 
 The analysis of possible moderators revealed that age, ApoE ε4 zygosity, and the 
presence of ApoE ε2 all significantly impacted the results.  Concerning age, the results 
indicated that increases in age results in significantly larger effect size differences 
between ApoE ε4 carriers and ApoE non-ε4 carriers on measures of episodic memory 
and global cognitive ability.  These findings are inconsistent with an earlier meta-analysis 
that found nonsignificant findings for age and effect size differences between ApoE ε4 
and ApoE non-ε4 carriers on measures of episodic memory and global cognitive ability 
(Small et al., 2004).  In addition, the magnitude and direction of the effect is also 
different as the previous meta-analysis found that effect sizes became smaller as the 
participants aged (Small et al., 2004).  It is thought that this discrepancy is the result of 
twice as many studies being included in the present analyses which increases the chances 
of finding significant results.  
 Controlling for the moderating effects of ApoE ε4 zygosity indicated that 
homozygous carriers performed significantly worse than heterozygotes on measures of 
episodic memory when being compared to homozygote ε3 carriers.  The middling sized 
effects are consistent with previous research that has documented the dose-effect 
relationship of ApoE ε4 and episodic memory (Berr et al., 1996; Caselli et al., 2002; 
Small et al., 2004; Yaffe, Cauley, Sands, & Browner, 1997).  This study was unable to 
replicate the previous meta-analysis that found a significant dose-effect relationship for 
measures of global cognitive ability.  It is thought that this is a result of fewer studies of 
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global cognitive ability being included in the current analyses; the same authors were 
contacted to obtain the data, but they did not respond with the necessary information. 
 Finally, the presence of ε2 was associated with higher scores than ApoE ε4 
carriers on measures of episodic memory.  Although the magnitude of the effect was 
small, the findings are still congruent with previously reported research studies (Small et 
al., 2004; Mondadori et al., 2007; Wilson, Bienias et al., 2002).  These results 
complement the findings that the presence of ApoE ε2 is positively associated with 
survival and longevity among older adults (Corder et al., 1996).  
 The results of the current meta-analysis help to extend and confirm the findings of 
Small et al. (2004).  The aforementioned study did not find significant deficits in 
perceptual speed while this meta-analysis detected a small effect.  In addition, both meta-
analyses confirm that the presence of ApoE ε4 is negatively associated with episodic 
memory, executive functioning, and overall global cognitive ability.  Again, both 
analyses support the notion that the presence of ApoE ε4 does not affect attention, verbal 
ability, visuospatial skill, or primary memory.  Also, both meta-analyses found a dose-
effect relationship for ApoE ε4 alleles with homozygotic carriers performing the worst on 
measures of episodic memory.  Finally, both analyses found a significant compensatory 
mechanism, albeit a small effect, with the presence of ApoE ε2 on episodic memory. 
Knowing that ApoE selectively affects only certain aspects of cognition raises the 
possibility that ApoE is somewhat isolated from certain areas of neural functioning.  
Recent studies have found that carriers of ApoE ε4 have significantly smaller hippocampi 
and amygdalae in both the left and right hemispheres of the brain when compared to 
homozygote ApoE ε3 carriers (den Heijer et al., 2002).  This finding could help explain 
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why ApoE ε4 carriers experience poorer performance on measures of episodic memory.  
Another recent study has shown that ApoE ε4 carriers employ a more economic use of 
learning-related neural resources without taxing their performance which raises the 
possibility that the presence of ApoE ε4 only impacts certain aspects of episodic memory 
(Mondadori et al., 2007).  Although ApoE ε4 only exerts small effects on cognitive 
functioning, the increasing identification of the specific aspects of cognitive functioning 
that are affected could help elucidate on the mechanism of action that ApoE ε4 uses to 
increase the chances of developing Alzheimer’s disease later in life. 
 The most prevalent limitation of the meta-analysis is the variability inherent in the 
testing instruments attempting to measure the same domain of functioning.  Many of the 
included cognitive measures have poor psychometric properties including inconsistent 
reliability and suspect validity.  Many of the measures tap into multiple cognitive 
domains simultaneously, making it difficult to isolate the effect to one specific function.  
Finally, most of the studies included in the global cognitive ability analyses used the Mini 
Mental State Examination (MMSE) as a screening device for Alzheimer’s disease.  The 
MMSE is deficit oriented making it very hard to avoid the ceiling effects to gain a more 
nuanced view of the differences between ApoE ε4 carriers and ApoE non-ε4 carriers on 
global cognitive functioning. 
 Another limitation is that the majority of the studies included in the analyses 
simply reported the scores for two groups: ApoE ε4+ and ApoE ε4-.  Very few studies 
presented the data with it divided according to the full ApoE genotype.  This makes it 
difficult to determine the presence of a dose-effect relationship between ApoE ε4 alleles 
and cognitive performance.  Also, many of the studies did not report on additional 
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information that could have been included as moderating variables.  Gender, education, 
and the presence of cardiovascular disease may all have an impact; however, the 
relatively small number of studies that documented this information made it impossible to 
create an accurate summary statistic. 
 Future research should focus on identifying which specific areas of episodic 
memory, global cognitive ability, executive functioning, and perceptual speed are most 
impacted by the presence of ApoE ε4.  It is thought that multiple standardized measures 
with a high correlation should be administered to avoid any losses in validity.  In 
addition, the impact of age needs to be more closely examined.  Small et al. (2004) 
indicated that increases in age mask the effects of ApoE ε4; however, the findings from 
this meta-analysis indicated the opposite.  Age enhanced the poorer performance 
exhibited by the ApoE ε4 carriers when compared to the ApoE non-ε4 carriers. 
 Additionally, future research should focus on determining which cognitive 
domains are impacted by mutations of the APP, PSEN1, and PSEN2 genes in 
nondemented, preclinical populations.  The studies currently in the literature on this topic 
do not include many cognitive measures and instead focus on the chromosomal 
differences.  Like the gains made with understanding ApoE, much can be learned about 
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Figure 1.  Scatterplot of age and effect size (Hedges’ g) for 
episodic memory.  Flory et al, 2000 and Levy et al, 2004 were 
excluded because of outlying effect sizes.  Kryscio, 2006 was 
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Figure 2.  Scatterplot of age and effect size (Hedges’ g) for 
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Figure 3.  Scatterplot of age and effect size (Hedges’ g) for 









































Figure 4.  Funnel plot of standard error and Hedges’ g to visually 
assess for publication bias.  n = 77. 
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